Dag Erik Jøssang

Statistics

Publications

Citations

H-Index

Active since

2018

Affiliations

Lytix Biopharma (Norway)(Current)

University of Bergen

Haukeland University Hospital

Institut Jules Bordet

University College London

Dag Erik Jøssang is an author at Lytix Biopharma (Norway) specializing in immunotherapy for solid tumors, immunotherapy, and immune response induction.

Publications per year

2018–2021

Publications

Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors

James Spicer, Aurélien Marabelle, Jean‐François Baurain et al. · Clinical Cancer Research · 2021 · 75 citations · Full text

Pharmacy, Oncology, Pharmacology +14

A phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates <i>de novo</i> T-cell responses and clinical benefit in patients with advanced solid tumors.

James Spicer, Aurélien Marabelle, Jean‐François Baurain et al. · Journal of Clinical Oncology · 2018 · 16 citations

Medicine, Immunology, Oncology +17

1–2 of 2